<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01535183</url>
  </required_header>
  <id_info>
    <org_study_id>SNUCH-1201</org_study_id>
    <nct_id>NCT01535183</nct_id>
  </id_info>
  <brief_title>Irinotecan Combination Chemotherapy for Refractory or Relapsed Brain Tumor in Children and Adolescents</brief_title>
  <official_title>Irinotecan, Vincristine, Etoposide, Carboplatin, and Cyclophosphamide for Refractory or Relapsed Brain Tumor in Children and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The outcome of pediatric refractory or relapsed brain tumor is very dismal. Standard&#xD;
      chemotherapy showed poor response to these patients. Although tandem high dose chemotherapy&#xD;
      with hematopoietic progenitor stem cell rescues has been chosen as a potentially curative&#xD;
      therapy for long term survival and better outcome is expected if tumor burden before&#xD;
      transplantation reduced by chemotherapy, effective salvage chemotherapy for tumor reduction&#xD;
      is not established yet. Irinotecan is a recently developed topoisomerase I inhibitor, and&#xD;
      there are preclinical and phase I, II data which proved practical effects in brain tumors. In&#xD;
      those studies, irinotecan was administered alone or in combination with one other drug.&#xD;
&#xD;
      Vincristine, etoposide, carboplatin, and cyclophosphamide have been used in many protocols&#xD;
      for brain tumors but the result was very poor in refractory or relapsed cases. However,&#xD;
      irinotecan can be effective with these multiple chemotherapeutic agents. According to the&#xD;
      pilot study of irinotecan in combination with vincristine, etoposide, carboplatin and&#xD;
      cyclophosphamide in the investigators center, 75% percent of total 12 patients reached more&#xD;
      than stable disease, and 2 patients got long term complete remission only with this&#xD;
      multi-agent combination chemotherapy. But the combination of irinotecan, vincristine,&#xD;
      etoposide, carboplatin, and cyclophosphamide is not clinically studied yet especially for&#xD;
      pediatric patients. To improve response rate and progression-free survival, the combination&#xD;
      chemotherapy of irinotecan, vincristine, etoposide, carboplatin, and cyclophosphamide is&#xD;
      designed for pediatric refractory or relapsed brain tumor.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate response rate (more than stable disease) of combination chemotherapy</measure>
    <time_frame>every 3 months</time_frame>
    <description>- Response Criteria : WHO-based &quot;Macdonald criteria&quot;, based on MRI&#xD;
Complete Response : disappearance of all enhancing tumor&#xD;
Partial Remission : more than 50 percentage decrease in the tumor measurement compared with the baseline scan&#xD;
Stable Disease : includes changes that do not meet criteria for CR, PR, or progressive disease (PD)&#xD;
Progressive Disease : more than 25 percentage increase in tumor measurement compared with the lesion size that defines the nadir, or smallest measurement, in the serial studies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate adverse event</measure>
    <time_frame>during chemotherapy and every follow up (3 times a week, up to 4 weeks)</time_frame>
    <description>- Toxicity evaluation : CTC version 4.0. A copy of the current version of the CTCAE can be downloaded from the CTEP home page (http://ctep.info.nih.gov).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate progression-free survival</measure>
    <time_frame>until last follow up (at least 1year)</time_frame>
    <description>- Kaplan-Meier method will be used for analysis.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Brain Tumor</condition>
  <arm_group>
    <arm_group_label>Irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan combination chemotherapy</intervention_name>
    <description>Irrinotecan 300㎎/㎡ d0 IVS mixed with D5W 500mL over 90min with atropine (-30 min)&#xD;
VCR 2㎎/㎡ d0 IV push&#xD;
Etoposide 100㎎/㎡ d0-d2 IV over 1hr&#xD;
Carboplatin 450㎎/㎡ d0 IV over 8hrs&#xD;
Cyclophosphamide 1,000㎎/㎡ d1 IVS with mesna</description>
    <arm_group_label>Irinotecan</arm_group_label>
    <other_name>Camptosar (Pfizer) or Campto (Yakult Honsha)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of brain tumor : embryonal brain tumor (medulloblastoma, CNS PNET, ATRT,&#xD;
             etc), intracranial germ cell tumor&#xD;
&#xD;
          -  Relapse or refractory state&#xD;
&#xD;
          -  Prior therapy : Patients must have fully recovered from the acute toxic effects of all&#xD;
             prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.&#xD;
             Patients are eligible 8 weeks from the day of stem cell infusion for autologous stem&#xD;
             cell transplant, if hematological and all other eligibility criteria are met.&#xD;
&#xD;
          -  Performance status: ECOG 0-2.&#xD;
&#xD;
          -  Patients must be free of significant functional deficits in major organs, but the&#xD;
             following eligibility criteria may be modified in individual cases.&#xD;
&#xD;
               1. Heart: a shortening fraction ≥ 28%&#xD;
&#xD;
               2. Liver: total bilirubin &lt; 2 × upper limit of normal; ALT &lt; 3 × upper limit of&#xD;
                  normal.&#xD;
&#xD;
               3. Kidney: creatinine &lt;2 × normal&#xD;
&#xD;
          -  Patients must lack any active viral infections or active fungal infection.&#xD;
&#xD;
          -  Patients (or one of parents if patients age &lt; 20) should sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or nursing women.&#xD;
&#xD;
          -  Malignant (except brain tumor) or nonmalignant illness that is uncontrolled or whose&#xD;
             control may be jeopardized by complications of study therapy.&#xD;
&#xD;
          -  Psychiatric disorder that would preclude compliance.&#xD;
&#xD;
          -  Patients who, in the opinion of the investigator, may not be able to comply with the&#xD;
             safety monitoring requirements of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyoung Jin Kang, M.D., ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Chongno-gu</state>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyoung Jin Kang, M.D., Ph.D</last_name>
      <phone>82-2-2072-3304</phone>
      <email>kanghj@snu.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Hyery Kim, M.D.</last_name>
      <phone>82-2-2072-3452</phone>
      <email>taban@hanmail.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>February 7, 2012</study_first_submitted>
  <study_first_submitted_qc>February 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2012</study_first_posted>
  <last_update_submitted>July 11, 2014</last_update_submitted>
  <last_update_submitted_qc>July 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>irinotecan</keyword>
  <keyword>brain tumor</keyword>
  <keyword>pediatrics</keyword>
  <keyword>salvage therapy</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

